Type 2 Diabetes (T2D) and obesity are interconnected modern global non-communicable epidemies.
T2D and obesity are risk factors for the development of several chronic diseases, posing a significant morbidity challenge.

Patients are driving demand for convenient, affordable, and effective, therapeutics.

Empagliflozin is a T2D medication that reduce T2D patients risks of cardiovascular disease, lower the risk of kidney disease, and has changed the outlook for T2D overall health.

Biota’s Empagliflozin non-swallowed oral film, is a convenient dosage form that can improve compliance of elderly and pediatric patients, who have swallowing difficulties.

Biota invites commercialization partnerships for first of its kind Empagliflozin oral film in India, and selected territories.

Reference

Christoph Wanner, Nathalia Duarte, Vikram Thanam & Egon Pfarr (2025) Safety of empagliflozin treatment in four clinical studies: a plain language summary, Current Medical Research and Opinion, 41:7, 1207-1217 https://www.tandfonline.com/share/GD9JWVGDF7NRSQAH43CC?target=10.1080/03007995.2025.2547905